Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients

University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK.
American Journal of Psychiatry (Impact Factor: 12.3). 09/2009; 166(10):1178-84. DOI: 10.1176/appi.ajp.2009.09020149
Source: PubMed


Acute administration of an antidepressant increases positive affective processing in healthy volunteers, an effect that may be relevant to the therapeutic actions of these medications. The authors investigated whether this effect is apparent in depressed patients early in treatment, prior to changes in mood and symptoms.
In a double-blind, placebo-controlled, between-groups randomized design, the authors examined the effect of a single 4-mg dose of the norepinephrine reuptake inhibitor reboxetine on emotional processing. Thirty-three depressed patients were recruited through primary care clinics and the community and matched to 31 healthy comparison subjects. Three hours after dosing, participants were given a battery of emotional processing tasks comprising facial expression recognition, emotional categorization, and memory. Ratings of mood, anxiety, and side effects were also obtained before and after treatment.
Depressed patients who received placebo showed reduced recognition of positive facial expressions, decreased speed in responding to positive self-relevant personality adjectives, and reduced memory for this positive information compared to healthy volunteers receiving placebo. However, this effect was reversed in patients who received a single dose of reboxetine, despite the absence of changes in subjective ratings of mood or anxiety.
Antidepressant drug administration modulates emotional processing in depressed patients very early in treatment, before changes occur in mood and symptoms. This effect may ameliorate the negative biases in information processing that characterize mood and anxiety disorders. It also suggests a mechanism of action compatible with cognitive theories of depression.

Download full-text


Available from: Elisa Favaron, Jan 02, 2014
  • Source
    • "Harding and colleagues trained rats to associate two different auditory cues with different emotional states associated with reward or punishment (Harding et al., 2004). When presented with an ambiguous tone, intermediate to the two that were trained, bias was exhibited toward the tone associated with the negative affective state under circumstances of chronic stress, much as has been shown in depressed humans (Harmer et al., 2009). There have since been many variants of these negative biasing procedures in rodents, notably the Affective Bias Test (Stuart et al., 2013) and in general, antidepressants, predictably, appear to reverse the bias induced by stressors.In addition to findings implicating a negative bias of informational processing in mood disorders, there are also reports describing an increase in impulsivity (including motor impulsivity) in mood disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive dysfunction may be a core feature of major depressive disorder (MDD) including affective processing bias, abnormal response to negative feedback, changes in decision making, and increased impulsivity. Accordingly, a translational medicine paradigm predicts clinical action of novel antidepressants by examining drug-induced changes in affective processing bias. With some exceptions, these concepts have not been systematically applied to preclinical models to test new chemical entities. The purpose of this review is to examine whether an empirically-derived behavioral screen for antidepressant drugs may screen for compounds, at least in part, by modulating an impulsive biasing of responding and altered decision-making. The differential-reinforcement-of low rate 72-s (DRL 72-s) schedule is an operant schedule with a documented fidelity for discriminating antidepressant drugs from non-antidepressant drugs. However, a theoretical basis for this empirical relationship has been lacking. Therefore, this review will discuss whether response bias towards impulsive behavior may be a critical screening characteristic of DRL behavior requiring long inter-response times to obtain rewards. This review will compare and contrast DRL behavior with the 5-choice serial reaction time test (5-CSRTT), a test specifically designed for assessing motoric impulsivity, with respect to psychopharmacological testing and the neural basis of distributed macrocircuits underlying these tasks. This comparison suggests that the existing empirical basis for the DRL 72-s schedule as a pharmacological screen for antidepressant drugs is complemented by a novel hypothesis that altering impulsive response bias for rodents trained on this operant schedule is a previously unrecognized theoretical cornerstone for this screening paradigm.
    Full-text · Article · Dec 2015 · Journal of Pharmacology and Experimental Therapeutics
    • "Additionally, chronic treatment with the selective serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine as well as the selective allosteric serotonin reuptake inhibitor (ASRI) escitalopram improved visual and verbal episodic memory in patients with major depressive disorder. Reboxetine was able to improve emotional memory already after a single dose in the absence of subjective mood changes (Harmer et al., 2009). However, the different conditions and tests used in the studies mentioned earlier make it hard to compare the effects of different drugs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients suffering from major depression often experience memory deficits even after the remission of mood symptoms, and many antidepressant drugs do not affect, or impair, memory in animals and humans. However, some antidepressant drugs, after a single dose, enhance cognition in humans (Harmer et al., 2009). To compare different classes of antidepressant drugs for their potential as memory enhancers, we used a version of the novel object recognition task in which rats spontaneously forget objects 24 hr after their presentation. Antidepressant drugs were injected systemically 30 min before or directly after the training phase (Session 1 [S1]). Post-S1 injections were used to test for specific memory-consolidation effects. The noradrenaline reuptake inhibitors reboxetine and atomoxetine, as well as the serotonin noradrenaline reuptake inhibitor duloxetine, injected prior to S1 significantly enhanced recognition memory. In contrast, the serotonin reuptake inhibitors citalopram and paroxetine and the cyclic antidepressant drugs desipramine and mianserin did not enhance recognition memory. Post-S1 injection of either reboxetine or citalopram significantly enhanced recognition memory, indicating an effect on memory consolidation. The fact that citalopram had an effect only when injected after S1 suggests that it may counteract its own consolidation-enhancing effect by interfering with memory acquisition. However, pretreatment with citalopram did not attenuate reboxetine's memory-enhancing effect. The D1/5-receptor antagonist SCH23390 blunted reboxetine's memory-enhancing effect, indicating a role of dopaminergic transmission in reboxetine-induced recognition memory enhancement. Our results suggest that antidepressant drugs specifically inhibiting noradrenaline reuptake enhance cognition and may be beneficial in the treatment of cognitive symptoms of depression.
    No preview · Article · Dec 2015 · Behavioral Neuroscience
    • "Among these task varieties, an identification task in which participants are asked to label facial emotions with given semantic emotional categories has frequently been used due to its simple task demand. Accumulated studies using this method have provided evidence that indicates abnormality of facial emotion recognition within depressed populations (Bhagwagar, Cowen, Goodwin, & Harmer, 2004; Gollan, Pane, McCloskey, & Coccaro, 2008; Harmer et al., 2009; Hayward, Goodwin, Cowen, & Harmer, 2005; Lawrence et al., 2004; Leppanen, Milders, Bell, Terriere, & Hietanen, 2004; Mikhailova, Vladimirova, Iznak, Tsusulkovskaya, & Sushko, 1996; Sheline et al., 2001; Surguladze et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a high prevalence of depression in adults with a history of childhood maltreatment. A negative cognitive bias is implicated in the etiology of depressive symptomatology and has also been found in physically abused children who show preferential processing of anger. However, how these biases mediate the link between childhood maltreatment and adult depression has not yet been clarified. This study involved 36 patients with depression (19 with and 17 without a history of childhood maltreatment) and 40 healthy controls (18 with and 22 without a history of childhood maltreatment). All participants were assessed using a facial emotion recognition task. Healthy individuals with a history of childhood maltreatment made significantly more errors in recognizing fear than anger. This difference between the number of errors for fear and anger was higher in healthy abused individuals than healthy nonabused individuals and depressed abused individuals. Resilient individuals with a history of childhood maltreatment but who have not developed depression show absence of a fear bias, which may help explain why they do not manifest depressive symptoms, despite their experiences of childhood maltreatment. In contrast, other individuals who become vulnerable to depression after childhood maltreatment show an amplified bias toward fear. © The Author(s) 2015.
    No preview · Article · Aug 2015 · Child Maltreatment
Show more